## **2017 Prescrire Information Awards**

The Information Awards focus on the information provided to Prescrire by the companies whose products we examined in the New Products section of our French edition in 2017.

HONOURS LIST	Dharma
(in alphabetical order)	Pharmac
	from the n
Outstanding:	this inforr
– EG Labo	drugs are
	tients fron
Followed by:	As part
- Advicenne	<i>crire</i> requ
- Arrow Génériques	nistrative
– Bioprojet Pharma – Delbert	ceutical o
- Medac	informatic <i>Prescrire</i>
– Mylan	company
– Nordic Pharma	mation.
	mation
RED CARDS	Informatio
(in alphabetical order)	2017. In 2
	101 pharm
	chose to b
<ul> <li>Bristol-Myers Squibb</li> </ul>	providing
– Effik	ponse to F
– Genévrier	placed on
– Genzyme (Sanofi Group) – Janssen Cilaq	panies ap rated as "
– Janssen Chag – Kyowa Kirin Pharma	larly usefu
– Menarini	and some
- MSD	out of the
– Pfizer	Other dr
<ul> <li>Swedish Orphan Biovitrum</li> </ul>	or all of o
<ul> <li>The Medicines Company</li> </ul>	only limite
– UCB Pharma	ponse and
	Some omi
Quality of information from pharmaceutical	Red Cards
companies	cies in the companie
We use a 4-point scale to rate the quality of the	Some of
information provided by companies in response	minimum
to our systematic requests	document
	They avoid
Company provided detailed information	the motion
including unpublished data and packaging items.	
	Still no im
Company provided information limited to	nothing ch
published regulatory data or packaging	panies pro
information.	some new
Company provided minimal information,	elsewhere ceutical co
mainly regulatory and packaging	
information.	by agreein health pro
	nearth pro
Company provided no information.	

Pharmaceutical companies hold a wealth of information on the drugs they market or withdraw from the market. They have a responsibility to share this information, in part to help ensure that their drugs are used appropriately and to protect patients from adverse effects.

As part of its systematic literature search, *Prescrire* requests clinical data, packaging, and administrative and regulatory information from pharmaceutical companies, then compares them with nformation obtained from other sources.

*Prescrire's* Information Awards reflect how each company assumes its responsibility to share information.

Information requested from 101 companies in 2017. In 2017, we requested information from 101 pharmaceutical companies. Some companies chose to be transparent and demonstrated this by providing detailed, relevant information in response to *Prescrire*'s requests. These companies are placed on the Honours List (8 out of the 101 companies approached for information in 2017). Those rated as "Outstanding" provided us with particularly useful and detailed information without delay and sometimes without being asked (1 company, out of the 101 approached).

Other drug companies failed to respond to some or all of our requests for information, or provided only limited data. Some of them delayed their response and failed to provide usable information. Some omitted the most important or sensitive data. Red Cards are given to highlight persistent deficiencies in the provision of information by some drug companies (12 of the 101 approached).

Some of the other 81 companies provided a bare minimum of information, sending us only limited documentation, sometimes after several reminders. They avoided a Red Card by simply going through the motions of sharing information.

Still no improvement in 2017. The years go by, yet nothing changes. On the whole, pharmaceutical companies provide *Prescrire* with a lot of information, some new and some that we have already obtained elsewhere. But as in previous years, few pharmaceutical companies embraced transparency in 2017 by agreeing to share all the data they hold with the health professionals who subscribe to *Prescrire*.

©Prescrire

► Translated from *Rev Prescrire* **February 2018** Volume 38 N° 412 • Page 88